New chemo rhythm aims to outsmart myeloma relapse

NCT ID NCT00871013

Ongoing Disease control Sponsor: University of Arkansas Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a new way of giving chemotherapy to people with high-risk multiple myeloma who have already had some treatment. Instead of high doses with long breaks, researchers give lower doses in shorter cycles to prevent cancer cells from regrowing. The goal is to improve remission rates and survival at two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Melphalan, Bortezomib (Velcade), Thalidomide
What this could lead to: If successful, this approach could extend remission and survival for high-risk myeloma patients who have already received treatment.
What could go wrong: This is a phase 2 trial, so results are preliminary. The lower-dose strategy may not improve outcomes, and side effects from the drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOMA

Contacts and locations

Locations

University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.